1 Weak Link at This Big Pharma

Eli Lilly (NYSE: LLY  ) , one of the biggest drugmakers in the world, continues to face headwinds as two of its top-selling pharmaceuticals are set to lose patent protection this year. However, one of its billion dollar blockbusters from 2012 --the antipsychotic drug Zyprexa -- has already lost patent protection. How has this expiration affected Eli Lilly's total business, and are there any parallels to one of its competitors in this space, beleaguered pharma company AstraZeneca (NYSE: AZN  ) ? Health care analyst Max Macaluso dives into this issue in the following video.

Can Eli Lilly defeat the patent cliff?
Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2255729, ~/Articles/ArticleHandler.aspx, 4/24/2014 5:26:07 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement